Epilepsy Severity Is Associated With Head Circumference and Growth Rate in Infants With Tuberous Sclerosis Complex.
Epilepsy
Growth curve
Head circumference
Tuberous sclerosis complex
Journal
Pediatric neurology
ISSN: 1873-5150
Titre abrégé: Pediatr Neurol
Pays: United States
ID NLM: 8508183
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
received:
25
08
2022
revised:
05
02
2023
accepted:
23
03
2023
pmc-release:
01
07
2024
medline:
16
6
2023
pubmed:
30
4
2023
entrez:
29
4
2023
Statut:
ppublish
Résumé
Abnormal brain growth in tuberous sclerosis complex (TSC) reflects abnormalities in cellular proliferation and differentiation and results in epilepsy and other neurological manifestations. Head circumference (HC) as a proxy for brain volume may provide an easily tracked clinical measure of brain overgrowth and neurological disease burden. This study investigated the relationship between HC and epilepsy severity in infants with TSC. Prospective multicenter observational study of children from birth to three years with TSC. Epilepsy data were collected from clinical history, and HC was collected at study visits at age three, six, nine, 12, 18, 24, and 36 months. Epilepsy severity was classified as no epilepsy, low epilepsy severity (one seizure type and one or two antiepileptic drugs [AEDs]), moderate epilepsy severity (either two to three seizure types and one to two AEDs or one seizure type and more than three AEDs), or high epilepsy severity (two to three seizure types and more than three AEDs). As a group, children with TSC had HCs approximately 1 S.D. above the mean World Health Organization (WHO) reference by age one year and demonstrated more rapid growth than the normal population reference. Males with epilepsy had larger HCs than those without. Compared with the WHO reference population, infants with TSC and no epilepsy or low or moderate epilepsy had an increased early HC growth rate, whereas those with severe epilepsy had an early larger HC but did not have a faster growth rate. Infants and young children with TSC have larger HCs than typical growth norms and have differing rates of head growth depending on the severity of epilepsy.
Sections du résumé
BACKGROUND
Abnormal brain growth in tuberous sclerosis complex (TSC) reflects abnormalities in cellular proliferation and differentiation and results in epilepsy and other neurological manifestations. Head circumference (HC) as a proxy for brain volume may provide an easily tracked clinical measure of brain overgrowth and neurological disease burden. This study investigated the relationship between HC and epilepsy severity in infants with TSC.
METHODS
Prospective multicenter observational study of children from birth to three years with TSC. Epilepsy data were collected from clinical history, and HC was collected at study visits at age three, six, nine, 12, 18, 24, and 36 months. Epilepsy severity was classified as no epilepsy, low epilepsy severity (one seizure type and one or two antiepileptic drugs [AEDs]), moderate epilepsy severity (either two to three seizure types and one to two AEDs or one seizure type and more than three AEDs), or high epilepsy severity (two to three seizure types and more than three AEDs).
RESULTS
As a group, children with TSC had HCs approximately 1 S.D. above the mean World Health Organization (WHO) reference by age one year and demonstrated more rapid growth than the normal population reference. Males with epilepsy had larger HCs than those without. Compared with the WHO reference population, infants with TSC and no epilepsy or low or moderate epilepsy had an increased early HC growth rate, whereas those with severe epilepsy had an early larger HC but did not have a faster growth rate.
CONCLUSIONS
Infants and young children with TSC have larger HCs than typical growth norms and have differing rates of head growth depending on the severity of epilepsy.
Identifiants
pubmed: 37119787
pii: S0887-8994(23)00095-4
doi: 10.1016/j.pediatrneurol.2023.03.015
pmc: PMC10330061
mid: NIHMS1887771
pii:
doi:
Substances chimiques
Anticonvulsants
0
Types de publication
Observational Study
Multicenter Study
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
26-32Subventions
Organisme : NICHD NIH HHS
ID : P50 HD105351
Pays : United States
Organisme : NINDS NIH HHS
ID : U01 NS082320
Pays : United States
Organisme : NINDS NIH HHS
ID : U54 NS092090
Pays : United States
Organisme : NINDS NIH HHS
ID : P20 NS080199
Pays : United States
Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Références
PLoS One. 2013 May 17;8(5):e63910
pubmed: 23691114
An Bras Dermatol. 2018 Jun;93(3):323-331
pubmed: 29924239
Epilepsia. 2010 Jul;51(7):1236-41
pubmed: 20041940
Acta Neuropathol. 2012 May;123(5):685-93
pubmed: 22327361
Proc Natl Acad Sci U S A. 2011 Nov 8;108(45):E1070-9
pubmed: 22025691
Orphanet J Rare Dis. 2015 Dec 02;10:154
pubmed: 26631248
Ann Neurol. 2021 Apr;89(4):726-739
pubmed: 33410532
Epilepsy Behav. 2017 May;70(Pt A):245-252
pubmed: 28457992
Ann Neurol. 2021 Feb;89(2):304-314
pubmed: 33180985
J Child Neurol. 2005 Oct;20(10):837-41
pubmed: 16417883
Dev Med Child Neurol. 1996 Feb;38(2):146-55
pubmed: 8603782
Pediatrics. 2017 Dec;140(6):
pubmed: 29101226
Epilepsia. 2015 Jul;56(7):1088-97
pubmed: 26122303
Epilepsia. 1998 Nov;39(11):1158-63
pubmed: 9821979
J Neurosci. 2008 May 21;28(21):5422-32
pubmed: 18495876
Cereb Cortex. 2014 Feb;24(2):315-27
pubmed: 23081885
Epilepsia. 2014 Apr;55(4):539-50
pubmed: 24512506
Am J Hum Genet. 2011 Jan 7;88(1):42-56
pubmed: 21194675
Neurotherapeutics. 2015 Jul;12(3):572-83
pubmed: 25986747
Dev Med Child Neurol. 2000 Nov;42(11):737-40
pubmed: 11104344
IEEE Trans Med Imaging. 2015 Jun;34(6):1349-61
pubmed: 25616008
Am J Med Genet A. 2006 Nov 1;140(21):2257-74
pubmed: 17022081
Epilepsy Res. 2008 May;79(2-3):139-45
pubmed: 18387786
Neuropediatrics. 2002 Oct;33(5):239-41
pubmed: 12536365